Mouse models of prostate cancer: Picking the best model for the question

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 377-397

  Grabowska, Magdalena M ^a   Degraff, David J ^a   Yu, Xiuping ^a   Jin, Ren Jie ^a   Chen, Zhenbang ^b   Borowsky, Alexander D ^c   Matusik, Robert J ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

LADY; Mouse models; Myc; Prostate cancer; PTEN; TRAMP

Indexed keywords

ANIMAL; DISEASE MODEL; HUMAN; MALE; MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS;

EID: 84905088552     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9487-8     Document Type: Review

References (158)

1. Howlader, N., Noone, A., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S., Kosary, C., Yu, M., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Lewis, D., Chen, H., Feuer, E. (1975 - 2010). SEER Cancer Statistics Review, National Cancer Institute. Available from URL: http://seer.cancer.gov/csr/1975- 2010/.Accessed 2 June 2013.
2. Surveillance, Epidemiology, and End Results (SEER). SEER Stat Fact Sheets: Prostate. Available from URL: http://seer.cancer.gov/statfacts/html/ prost.html. Accessed May 2013.
3. Miller, A. B. (2012). New data on prostate-cancer mortality after PSA screening. New England Journal of Medicine, 366, 1047-1048.
4. Stanford, J., Stephenson, R., Coyle, L., Cerhan, J., Correa, R., Eley, J., et al. (1999). Survival. Prostate cancer trends, 1973 -1995. Bethesda: SEER Program, National Cancer Institute.
5. Suwa, T., Nyska, A., Haseman, J. K., Mahler, J. F., &Maronpot, R. R. (2002). Spontaneous lesions in control B6C3F1 mice and recommended sectioning of male accessory sex organs. Toxicologic Pathology, 30, 228-234. (Pubitemid 34293047)
6. Vis, A. N., & Schröder, F. H. (2009). Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU International, 104, 438-448.
7. Sun, Y., Niu, J.,& Huang, J. (2009). Neuroendocrine differentiation in prostate cancer. American Journal of Translation Research, 1, 148-162.
8. Morrissey, C., & Vessella, R. L. (2007). The role of tumor micro-environment in prostate cancer bone metastasis. Journal of Cellular Biochemistry, 101, 873-886.
9. Shappell, S. B., Thomas, G. V., Roberts, R. L., Herbert, R., Ittmann, M.M., Rubin, M. A., et al. (2004). Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Research, 64, 2270-2305. (Pubitemid 38339483)
10. Ittmann, M., Huang, J., Radaelli, E., Martin, P., Signoretti, S., Sullivan, R., et al. (2013). Animal models of human prostate cancer: the consensus report of the New York meeting of theMouseModels of Human Cancers Consortium Prostate Pathology Committee. Cancer Research, 73, 2718-2736.
11. Ousset, M., Van Keymeulen, A., Bouvencourt, G., Sharma, N., Achouri, Y., Simons, B. D., et al. (2012).Multipotent and unipotent progenitors contribute to prostate postnatal development. Nature Cell Biology, 14, 1131-1138.
12. Liu, J., Pascal, L. E., Isharwal, S., Metzger, D., Ramos Garcia, R., Pilch, J., et al. (2011). Regenerated luminal epithelial cells are derived from preexisting luminal epithelial cells in adult mouse prostate. Molecular Endocrinology, 25, 1849-1857.
13. Choi, N., Zhang, B., Zhang, L., Ittmann, M., & Xin, L. (2012). Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell, 21, 253-265.
14. Lu, T.-L., Huang, Y.-F., You, L.-R., Chao, N.-C., Su, F.-Y., Chang, J.-L., et al. (2013). Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. The American Journal of Pathology, 182, 975-991.
15. Wang, Z. A., Mitrofanova, A., Bergren, S. K., Abate-Shen, C., Cardiff, R. D., Califano, A., et al. (2013). Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nature Cell Biology, 15, 274-283.
16. Hu, Y., Ippolito, J. E., Garabedian, E. M., Humphrey, P. A., & Gordon, J. I. (2002). Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. Journal of Biological Chemistry, 277, 44462-44474. (Pubitemid 36157881)
17. Garabedian, E. M., Humphrey, P. A., & Gordon, J. I. (1998). A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 15382-15387. (Pubitemid 29018707)
18. Chokkalingam, A. P., Nyrén, O., Johansson, J.-E., Gridley, G., McLaughlin, J. K., Adami, H.-O., et al. (2003). Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia. Cancer, 98, 1727-1734.
19. Bostwick, D. G., Liu, L., Brawer, M. K., & Qian, J. (2004). High-grade prostatic intraepithelial neoplasia. Revista de Urología, 6, 171-179.
20. Reyes, A., Swanson, P. E., Carbone, J. M., & Humphrey, P. A. (1997). Unusual histologic types of high-grade prostatic intraepithelial neoplasia. The American Journal of Surgical Pathology, 21, 1215-1222. (Pubitemid 27422322)
21. Gingrich, J. R., Barrios, R. J., Foster, B. A., & Greenberg, N. M. (1999). Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer and Prostatic Disease, 2, 70-75. (Pubitemid 29259935)
22. Park, J.-H., Walls, J. E., Galvez, J. J., Kim, M., Abate-Shen, C., Shen, M. M., et al. (2002). Prostatic intraepithelial neoplasia in genetically engineered mice. The American Journal of Pathology, 161, 727-735. (Pubitemid 36142181)
23. Humphrey, P. A. (2012). Histological variants of prostatic carcinoma and their significance. Histopathology, 60, 59-74.
24. Wang, W., & Epstein, J. I. (2008). Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases. The American Journal of Surgical Pathology, 32, 65-71.
25. Palmgren, J. S., Karavadia, S. S., & Wakefield, M. R. (2007). Unusual and underappreciated: small cell carcinoma of the prostate. Seminar in Oncology, 34, 22-29. (Pubitemid 46161758)
26. Hansel, D. E.,& Epstein, J. I. (2006). Sarcomatoid carcinoma of the prostate: a study of 42 cases. American Journal of Surgical Pathology, 30, 1316-1321.
27. Martin, P., Liu, Y.-N., Pierce, R., Abou-Kheir, W., Casey, O., Seng, V., et al. (2011). Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. The American Journal of Pathology, 179, 422-435.
28. Acevedo, V. D., Gangula, R. D., Freeman, K.W., Li, R., Zhang, Y., Wang, F., et al. (2007). Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell, 12, 559-571. (Pubitemid 350199071)
29. Mulholland, D. J., Kobayashi, N., Ruscetti, M., Zhi, A., Tran, L.M., Huang, J., et al. (2012). Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Research, 72, 1878-1889.
30. Vinall, R. L., Chen, J. Q., Hubbard, N. E., Sulaimon, S. S., Shen, M. M., DeVereWhite, R.W., et al. (2012). Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression. Disease Models & Mechanisms, 5, 914-920.
31. Ayala, G. E., Muezzinoglu, B., Hammerich, K. H., Frolov, A., Liu, H., Scardino, P. T., et al. (2011). Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. The American Journal of Pathology, 178, 79-87.
32. Ayala, G., Tuxhorn, J. A., Wheeler, T. M., Frolov, A., Scardino, P. T., Ohori, M., et al. (2003). Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clinical Cancer Research, 9, 4792-4801. (Pubitemid 37323282)
33. Hayward, S. W., Wang, Y., Cao, M., Hom, Y. K., Zhang, B., Grossfeld, G. D., et al. (2001). Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Research, 61, 8135-8142. (Pubitemid 33091604)
34. Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., et al. (2006). Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic. Asymptomatic hormone refractory prostate cancer. Journal of Clinical Oncology, 24, 3089-3094. (Pubitemid 46638945)
35. Hess, K. R., Varadhachary, G. R., Taylor, S. H., Wei, W., Raber, M. N., Lenzi, R., et al. (2006). Metastatic patterns in adenocarcinoma. Cancer, 106, 1624-1633.
36. Nandana, S., Ellwood-Yen, K., Sawyers, C., Wills, M., Weidow, B., Case, T., et al. (2010). Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model. The Prostate, 70, 591-600.
37. Ding, Z., Wu, C.-J., Jaskelioff, M., Ivanova, E., Kost-Alimova, M., Protopopov, A., et al. (2012). Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell, 148, 896-907.
38. Gingrich, J. R., Barrios, R. J., Morton, R.A., Boyce, B. F., DeMayo, F. J., Finegold, M. J., et al. (1996). Metastatic prostate cancer in a transgenic mouse. Cancer Research, 56, 4096-4102. (Pubitemid 26304996)
39. Prostate Cancer Trialists' Collaborative G. (1995). Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. The Lancet, 346, 265-269.
40. Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367, 1187-1197.
41. Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., et al. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology, 13, 983-992.
42. Greenberg, N. M., DeMayo, F. J., Sheppard, P. C., Barrios, R., Lebovitz, R., Finegold, M., et al. (1994). The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Molecular Endocrinology, 8, 230-239. (Pubitemid 24067110)
43. Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M., Desai, N., Young, P., et al. (1999). Roles for Nkx3.1 in prostate development and cancer. Genes and Development, 13, 966-977. (Pubitemid 29200980)
44. Tanaka, M., Komuro, I., Inagaki, H., Jenkins, N. A., Copeland, N. G., & Izumo, S. (2000). Nkx3.1, a murine homolog of Drosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands. Developmental Dynamics, 219, 248-260.
45. Rennie, P. S., Bruchovsky, N., Leco, K. J., Sheppard, P. C., McQueen, S. A., Cheng, H., et al. (1993). Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Molecular Endocrinology, 7, 23-36. (Pubitemid 23047202)
46. Zhang, J., Thomas, T. Z., Kasper, S., & Matusik, R. J. (2000). A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology, 141, 4698-4710. (Pubitemid 32055150)
47. Bianchi-Frias, D., Pritchard, C., Mecham, B., Coleman, I., & Nelson, P. (2007). Genetic background influences murine prostate gene expression: implications for cancer phenotypes. Genome Biology, 8, R117.
48. Chiaverotti, T., Couto, S. S., Donjacour, A., Mao, J.-H., Nagase, H., Cardiff, R. D., et al. (2008). Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. The American journal of pathology, 172, 236-246. (Pubitemid 351186384)
49. Ahuja, D., Saenz-Robles, M. T., & Pipas, J. M. (2005). SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene, 24, 7729-7745. (Pubitemid 41670675)
50. Maroulakou, I. G., Anver, M., Garrett, L., & Green, J. E. (1994). Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proceedings of the National Academy of Sciences of the United States of America, 91, 11236-11240. (Pubitemid 24349661)
51. Greenberg, N.M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., et al. (1995). Prostate cancer in a transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America, 92, 3439-3443.
52. Gingrich, J. R., Barrios, R. J., Kattan, M.W., Nahm, H. S., Finegold, M. J., & Greenberg, N. M. (1997). Androgen-independent prostate cancer progression in the TRAMP model. Cancer Research, 57, 4687-4691. (Pubitemid 27468967)
53. Kaplan-Lefko, P. J., Chen, T.-M., Ittmann, M. M., Barrios, R. J., Ayala, G. E., Huss, W. J., et al. (2003). Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. The Prostate, 55, 219-237. (Pubitemid 36532401)
54. Han, G., Foster, B. A., Mistry, S., Buchanan, G., Harris, J. M., Tilley, W. D., et al. (2001). Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. Journal of Biological Chemistry, 276, 11204-11213. (Pubitemid 38089305)
55. Irshad, S., & Abate-Shen, C. (2012). Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer and Metastasis Reviews, 32, 1-14.
56. Ahmad, I., Sansom, O. J., & Leung, H. Y. (2009). The role of murine models of prostate cancer in drug target discovery and validation. Expert Opinion on Drug Discovery, 4, 879-888.
57. Kasper, S., Sheppard, P. C., Yan, Y., Pettigrew, N., Borowsky, A. D., Prins, G., et al. (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Laboratory Investigation, 78, i-xv.
58. Klezovitch, O., Chevillet, J., Mirosevich, J., Roberts, R. L., Matusik, R. J., & Vasioukhin, V. (2004). Hepsin promotes prostate cancer progression and metastasis. Cancer Cell, 6, 185-195. (Pubitemid 39485690)
59. Masumori, N., Thomas, T. Z., Chaurand, P., Case, T., Paul, M., Kasper, S., et al. (2001). A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Research, 61, 2239-2249. (Pubitemid 32692054)
60. Palmer, J., Venkateswaran, V., Fleshner, N. E., Klotz, L. H., & Cox, M. E. (2008). The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate. The Prostate, 68, 345-353. (Pubitemid 351342640)
61. Venkateswaran, V., Klotz, L. H., Ramani, M., Sugar, L. M., Jacob, L. E., Nam, R. K., et al. (2009). A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model. Cancer Prev Res (Phila Pa), 2, 473-483.
62. Guo, Y., Jacobs, S. C.,& Kyprianou, N. (1997). Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β1) type I and type II receptors in human prostate cancer. International Journal of Cancer, 71, 573-579. (Pubitemid 27239366)
63. Tu, W. H., Thomas, T., Masumori, N., Bhowmick, N., Gorska, A., Shyr, Y., et al. (2003). The loss of TGF-β signaling promotes prostate cancer metastasis. Neoplasia, 5, 267-277. (Pubitemid 36754056)
64. Yu, X., Wang, Y., DeGraff, D. J., Wills, M. L., & Matusik, R. J. (2011). Wnt/Beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene, 30, 1868-1879.
65. Gounari, F., Signoretti, S., Bronson, R., Klein, L., Sellers, W. R., Kum, J., et al. (2002). Stabilization of b-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdiferentiation of other secretory epithelia. Oncogene, 21, 4099-4107. (Pubitemid 34712877)
66. Bruxvoort, K. J., Charbonneau, H. M., Giambernardi, T. A., Goolsby, J. C., Qian, C.-N., Zylstra, C. R., et al. (2007). Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Research, 67, 2490-2496. (Pubitemid 46548933)
67. Zhou, Z., Flesken-Nikitin, A., Corney, D. C., Wang, W., Goodrich, D. W., Roy-Burman, P., et al. (2006). Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Research, 66, 7889-7898. (Pubitemid 44299151)
68. Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005). Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancermodel. Cancer Research, 65, 10243-10254. (Pubitemid 41743716)
69. Phillips, S. M., Barton, C.M., Lee, S. J., Morton, D. G., Wallace, D. M., Lemoine, N. R., et al. (1994). Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. British Journal of Cancer, 70, 1252-1257. (Pubitemid 24358972)
70. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F., & Allred, D. C. (1993). p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Research, 53, 3369-3373.
71. Saric, T., Brkanac, Z., Troyer, D. A., Padalecki, S. S., Sarosdy, M., Williams, K., et al. (1999). Genetic pattern of prostate cancer progression. International Journal of Cancer, 81, 219-224. (Pubitemid 29144750)
72. Qi, J., Nakayama, K., Cardiff, R. D., Borowsky, A. D., Kaul, K., Williams, R., et al. (2010). Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell, 18, 23-38.
73. Spence, A. M., Sheppard, P. C., Davie, J. R., Matuo, Y., Nishi, N., McKeehan, W. L., et al. (1989). Regulation of a bifunctionalmRNA results in synthesis of secreted and nuclear probasin. Proceedings of the National Academy of Sciences of the United States of America, 86, 7843-7847. (Pubitemid 19265282)
74. Maddison, L. A., Nahm, H., DeMayo, F., & Greenberg, N. M. (2000). Prostate specific expression of Cre recombinase in transgenic mice. Genesis, 26, 154-156. (Pubitemid 30158106)
75. Wu, X., Wu, J., Huang, J., Powell, W. C., Zhang, J., Matusik, R. J., et al. (2001). Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mechanisms of Development, 101, 61-69. (Pubitemid 32186310)
76. Song, M. S., Salmena, L., & Pandolfi, P. P. (2012). The functions and regulation of the PTEN tumour suppressor. Nature Reviews in Molecular and Cell Biology, 13, 283-296.
77. Cantley, L. C., & Neel, B. G. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proceedings of the National Academy of Sciences of the United States of America, 96, 4240-4245.
78. Yoshimoto, M., Cutz, J.-C., Nuin, P. A. S., Joshua, A. M., Bayani, J., Evans, A. J., et al. (2006). Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genetics and Cytogenetics, 169, 128-137. (Pubitemid 44287105)
79. Holcomb, I. N., Young, J. M., Coleman, I.M., Salari, K., Grove, D. I., Hsu, L., et al. (2009). Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Research, 69, 7793-7802.
80. Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression. Nature Genetics, 19, 348-355. (Pubitemid 28357906)
81. Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., Barrantes, I. D. B., et al. (1998). High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Current biology, CB 8, 1169-1178.
82. Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., et al. (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proceedings of the National Academy of Sciences of the United States of America, 96, 1563-1568. (Pubitemid 29098491)
83. Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., et al. (2003). Pten dose dictates cancer progression in the prostate. PLoS Biology, 1, e59.
84. Stambolic, V., Tsao, M.-S., Macpherson, D., Suzuki, A., Chapman, W. B., & Mak, T. W. (2000). High incidence of breast and endometrial neoplasia resembling human cowden syndrome in Pten+/-mice. Cancer Research, 60, 3605-3611. (Pubitemid 30482183)
85. Vis, A. N., Noordzij, M. A., Fitoz, K., Wildhagen, M. F., Schroder, F. H., & van der Kwast, T. H. (2000). Prognostic value of cell cycle proteins p27kip1 and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. The Journal of Urology, 164, 2156-2161.
86. Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S. S., et al. (1998). Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. Journal of the National Cancer Institute, 90, 1284-1291. (Pubitemid 28433473)
87. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., & Pandolfi, P. P. (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nature Genetics, 27, 222-224. (Pubitemid 32157454)
88. Sciavolino, P. J., Abrams, E.W., Yang, L., Austenberg, L. P., Shen, M. M., & Abate-Shen, C. (1997). Tissue-specific expression of murine Nkx3.1 in the male urogenital system. Developmental Dynamics, 209, 127-138. (Pubitemid 27188345)
89. Kim, M. J., Cardiff, R. D., Desai, N., Banach-Petrosky, W. A., Parsons, R., Shen, M. M., et al. (2002). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 99, 2884-2889. (Pubitemid 34240555)
90. Bowen, C., Bubendorf, L., Voeller, H. J., Slack, R., Willi, N., Sauter, G., et al. (2000). Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Research, 60, 6111-6115.
91. Schneider, A., Brand, T., Zweigerdt, R., & Arnold, H.-H. (2000). Targeted disruption of the Nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate. Mechanisms of Development, 95, 163-174. (Pubitemid 30440803)
92. Abdulkadir, S. A., Magee, J.A., Peters, T. J., Kaleem, Z., Naughton, C. K., Humphrey, P. A., et al. (2002). Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Molecular and Cellular Biology, 22, 1495-1503. (Pubitemid 34150785)
93. Kim, M. J., Bhatia-Gaur, R., Banach-Petrosky, W. A., Desai, N., Wang, Y., Hayward, S. W., et al. (2002). Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Research, 62, 2999-3004. (Pubitemid 34602384)
94. Abate-Shen, C., Banach-Petrosky, W. A., Sun, X., Economides, K. D., Desai, N., Gregg, J. P., et al. (2003). Nkx3.1; pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Research, 63, 3886-3890. (Pubitemid 36917899)
95. Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., et al. (2003). Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-221. (Pubitemid 37163835)
96. Waltering, K. K., Urbanucci, A., & Visakorpi, T. (2012). Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Molecular and Cellular Endocrinology, 360, 38-43.
97. Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., et al. (2004). Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. The American Journal of Pathology, 164, 217-227. (Pubitemid 38364606)
98. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., et al. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics, 9, 401-406.
99. Liao, C.-P., Zhong, C., Saribekyan, G., Bading, J., Park, R., Conti, P. S., et al. (2007).Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Research, 67, 7525-7533. (Pubitemid 47206583)
100. Zhang, W., Zhu, J., Efferson, C. L., Ware, C., Tammam, J., Angagaw, M., et al. (2009). Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Research, 69, 7466-7472.
101. Mulholland David, J., Tran Linh, M., Li, Y., Cai, H., Morim, A., Wang, S., et al. (2011). Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell, 19, 792-804.
102. Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 436, 725-730. (Pubitemid 41117277)
103. Ma, X., der Made AC, Z.-v., Autar, B., van der Korput, H. A., Vermeij, M., van Duijn, P., et al. (2005). Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Research, 65, 5730-5739. (Pubitemid 40911176)
104. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine, 10, 594-601. (Pubitemid 38796850)
105. Ratnacaram, C. K., Teletin, M., Jiang, M., Meng, X., Chambon, P., & Metzger, D. (2008). Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 105, 2521-2526. (Pubitemid 351520546)
106. Wang, X., Julio, M. K.-d., Economides, K. D., Walker, D., Yu, H., Halili, M.V., et al. (2009). A luminal epithelial stemcell that is a cell of origin for prostate cancer. Nature, 461, 495-500.
107. Floc'h, N., Kinkade, C. W., Kobayashi, T., Aytes, A., Lefebvre, C., Mitrofanova, A., et al. (2012). Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Research, 72, 4483-4493.
108. Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007). A newmousemodel to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes and Development, 21, 379-384.
109. Wang, J., Kobayashi, T., Floc'h, N., Kinkade, C. W., Aytes, A., Dankort, D., et al. (2012). B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Research, 72, 4765-4776.
110. Aytes, A., Mitrofanova, A., Kinkade, C. W., Lefebvre, C., Lei, M., Phelan, V., et al. (2013). ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 110, E3506-E3515.
111. Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., &Witte, O. N. (2010). Identification of a cell of origin for human prostate cancer. Science, 329, 568-571.
112. Aitchison, A. A., Veerakumarasivam, A., Vias, M., Kumar, R., Hamdy, F. C., Neal, D. E., et al. (2008). Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. The Prostate, 68, 661-674. (Pubitemid 351614644)
113. Ding, Z., Wu, C.-J., Chu, G. C., Xiao, Y., Ho, D., Zhang, J., et al. (2011). SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature, 470, 269-273.
114. Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310, 644-648. (Pubitemid 41528150)
115. Tomlins, S. A., Mehra, R., Rhodes, D. R., Smith, L. R., Roulston, D., Helgeson, B. E., et al. (2006). TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Research, 66, 3396-3400.
116. Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 448, 595-599. (Pubitemid 47206938)
117. Klezovitch, O., Risk, M., Coleman, I., Lucas, J.M., Null, M., True, L. D., et al. (2008). A causal role for ERG in neoplastic transformation of prostate epithelium. Proceedings of the National Academy of Sciences of the United States of America, 105, 2105-2110. (Pubitemid 351439472)
118. Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., et al. (2008). The role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia, 10, 177-188. (Pubitemid 351240884)
119. Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., et al. (2009). Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics, 41, 619-624.
120. King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., et al. (2009). Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genetics, 41, 524-526.
121. Baena, E., Shao, Z., Linn, D. E., Glass, K., Hamblen, M. J., Fujiwara, Y., et al. (2013). ETV1 directs androgen metabolism and confers aggressive prostate cancer in targetedmice and patients. Genes and Development, 27, 683-698.
122. Yoshimoto, M., Joshua, A. M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Ludkovski, O., et al. (2008). Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Modern Pathology, 21, 1451-1460.
123. Zhong, C., Saribekyan, G., Liao, C.-P., Cohen, M. B., & Roy-Burman, P. (2006). Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Research, 66, 2188-2194.
124. Nguyen, A. H. T., Tremblay, M., Haigh, K., Koumakpayi, I. H., Paquet, M., Pandolfi, P. P., et al. (2013). Gata3 antagonizes cancer progression in Pten-deficient prostates. HumanMolecular Genetics, 22, 2400-2410.
125. Nacerddine, K., Beaudry, J.-B., Ginjala, V., Westerman, B., Mattiroli, F., Song, J.-Y., van der Poel, H., Ponz, O. B., Pritchard, C., Cornelissen-Steijger, P., Zevenhoven, J., Tanger, J., Sixma, E., Ganesan, T. K., & van Lohuizen, M. (2012). Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. The Journal of Clinical Investigation, 122, 1920-1932.
126. Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., et al. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes and Development, 15, 3243-3248. (Pubitemid 34008190)
127. Carver Brett, S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., et al. (2011). Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell, 19, 575-586.
128. Svensson, R. U., Haverkamp, J. M., Thedens, D. R., Cohen, M. B., Ratliff, T. L., & Henry, M. D. (2011). Slow disease progression in a C57BL/6 Pten-deficient mouse model of prostate cancer. The American Journal of Pathology, 179, 502-512.
129. Gurel, B., Iwata, T., Koh, C. M., Jenkins, R. B., Lan, F., Van Dang, C., et al. (2008). Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Modern Pathology, 21, 1156-1167.
130. Fleming, W. H., Hamel, A., MacDonald, R., Ramsey, E., Pettigrew, N. M., Johnston, B., et al. (1986). Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Research, 46, 1535-1538. (Pubitemid 16048309)
131. Koh, C. M., Bieberich, C. J., Dang, C. V., Nelson, W. G., Yegnasubramanian, S., & De Marzo, A. M. (2010). MYC and prostate cancer.
132. Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., et al. (2003). Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell, 4, 223-238. (Pubitemid 37163836)
133. Iwata, T., Schultz, D., Hicks, J., Hubbard, G. K., Mutton, L. N., Lotan, T. L., et al. (2010). MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS ONE, 5, e9427.
134. Jin, R. J., Lho, Y., Connelly, L., Wang, Y., Yu, X., Saint Jean, L., et al. (2008). The nuclear factor-KappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Research, 68, 6762-6769.
135. Clegg, N. J., Couto, S. S., Wongvipat, J., Hieronymus, H., Carver, B. S., Taylor, B. S., et al. (2011). MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS ONE, 6, e17449.
136. Roh, M., Kim, J., Song, C., Wills, M., & Abdulkadir, S. A. (2006). Transgenic mice for Cre-inducible overexpression of the oncogenes c-MYC and Pim-1 in multiple tissues. Genesis, 44, 447-453. (Pubitemid 44684991)
137. Kim, J., Roh, M., Doubinskaia, I., Algarroba, G. N., Eltoum, I.-E. A., & Abdulkadir, S. A. (2012). A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene, 31, 322-332.
138. Hensley, P., & Kyprianou, N. (2012). Modeling prostate cancer in mice: limitations and opportunities. Journal of Andrology, 33, 133-144.
139. Shen, M. M., & Abate-Shen, C. (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes and Development, 24, 1967-2000.
140. Jeet, V., Russell, P., & Khatri, A. (2010). Modeling prostate cancer: a perspective on transgenic mouse models. Cancer and Metastasis Reviews, 29, 123-142.
141. Marcus, D. M., Goodman, M., Jani, A. B., Osunkoya, A. O., & Rossi, P. J. (2012). A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer and Prostatic Disease, 15, 283-288.
142. Jin, R. J., Wang, Y., Masumori, N., Ishii, K., Tsukamoto, T., Shappell, S. B., et al. (2004). NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Research, 64, 5489-5495. (Pubitemid 39006573)
143. Stanbrough, M., Leav, I., Kwan, P. W. L., Bubley, G. J., & Balk, S. P. (2001). Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proceedings of the National Academy of Sciences of the United States of America, 98, 10823-10828. (Pubitemid 32878704)
144. Albertelli, M. A., Scheller, A., Brogley, M., & Robins, D. M. (2006). Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Molecular Endocrinology, 20, 1248-1260. (Pubitemid 43801229)
145. Zhu, C., Luong, R., Zhuo, M., Johnson, D. T., McKenney, J. K., Cunha, G. R., et al. (2011). Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate. Journal of Biological Chemistry, 286, 33478-33488.
146. Zhang, X., Morrissey, C., Sun, S., Ketchandji, M., Nelson, P. S., True, L. D., et al. (2011). Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE, 6, e27970.
147. Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., et al. (2010). Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. The Journal of Clinical Investigation, 120, 2715-2730.
148. Liu, G., Sprenger, C., Sun, S., Epilepsia, K. S., Haugk, K., Zhang, X., et al. (2013). AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia (NY), 15, 1009-1017.
149. Cunha, G. R. (2008). Mesenchymal-epithelial interactions: past, present, and future. Differentiation, 76, 578-586.
150. Ricke, E. A., Williams, K., Lee, Y.-F., Couto, S., Wang, Y., Hayward, S. W., et al. (2012). Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis, 33, 1391-1398.
151. Lai, K.-P., Yamashita, S., Huang, C.-K., Yeh, S., & Chang, C. (2012). Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines. EMBO Molecular Medicine, 4, 791-807.
152. Bhowmick, N., Chytil, A., Plieth, D., Gorska, A., Dumont, N., Shappell, S., et al. (2004). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science, 303, 848-851. (Pubitemid 38174665)
153. Li, X., Placencio, V., Iturregui, J.M., Uwamariya, C., Sharif-Afshar, A. R., Koyama, T., et al. (2008). Prostate tumor progression is mediated by a paracrine TGF-[beta]/Wnt3a signaling axis. Oncogene, 27, 7118-7130.
154. Franco, O. E., & Hayward, S. W. (2012). Chapter nine - targeting the tumor stroma as a novel therapeutic approach for prostate cancer. In S. M. S. Keiran (Ed.), Advances in pharmacology (pp. 267-313). Bethesda: Academic.
155. Beltran, H., Rickman, D. S., Park, K., Chae, S. S., Sboner, A., MacDonald, T. Y., et al. (2011). Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery, 1, 487-495.
156. Mosquera, J. M., Beltran, H., Park, K., MacDonald, T. Y., Robinson, B. D., Tagawa, S. T., et al. (2013). Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia, 15, 1-10.
157. Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., et al. (2010). Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 107, 16759-16765.
158. Crnalic, S., Hörnberg, E., Wikström, P., Lerner, U. H., Tieva, Å., Svensson, O., et al. (2010). Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocrine-Related Cancer, 17, 885-895. Disparities Disparities Disparities